Navigation Links
New treatment method safe, effective for advanced melanoma patients
Date:6/5/2010

CHICAGO, June 5 Patients undergoing treatment for melanoma that has spread to the liver may respond well to chemotherapy delivered directly into the liver's blood vessels, according to a study sponsored by the National Cancer Institute and Delcath Systems Inc., and led by James F. Pingpank, M.D., associate professor of surgery, University of Pittsburgh School of Medicine, and surgical oncologist with UPMC Cancer Centers. The results will be disclosed in an oral presentation on June 5 in Chicago at the 46th annual meeting of the American Society of Clinical Oncology (ASCO).

"Once melanoma spreads to the liver, a patient's life expectancy typically ranges from six to nine months," said Dr. Pingpank. "We hoped this study would not only show an increase in progression-free survival rates for these patients, but also lead to a standard of care for the disease."

The phase III trial enrolled 93 patients from 10 different sites across the country between February 2006 and October 2009. Its primary goal was to double the length of hepatic progression-free survival for patients with melanoma that had spread to the liver. Patients received either percutaneous hepatic perfusion (PHP) with the drug melphalan, meaning the chemotherapy was delivered directly into the blood vessels of the liver, or the treatment considered the best alternative regimen by their treating physician. If a patient not receiving PHP had disease progression, he or she could cross over to the PHP arm of the trial.

"Not only did we achieve our goal, we surpassed it," said Dr. Pingpank. "This is particularly exciting because so far oncologists haven't been able to recommend a standard of care for patients with melanoma that has spread to the liver. PHP appears to control tumors in the liver and extend life expectancy for these patients, whether their melanoma began as skin cancer or as ocular melanoma, a less common form of the disease that starts in the eye. Fifty percent of ocular melanoma patients will experience liver metastasis, so these findings are crucial for them."

Melanoma is a rare form of cancer, but it causes the majority of skin cancer-related deaths. Each year, approximately 160,000 new cases are diagnosed worldwide. Ocular melanoma will be diagnosed in approximately 2,500 adults this year.


'/>"/>

Contact: Courtney McCrimmon
McCrimmonCP@upmc.edu
412-715‑8894
University of Pittsburgh Schools of the Health Sciences
Source:Eurekalert

Related medicine news :

1. Combination treatment regimen not effective against advanced melanoma
2. Researchers Report Treatment Headway Against Lung Cancer
3. Nasendoscopy proves useful in predicting treatment success in sleep apnea patients
4. Mount Sinai researchers approaching universal treatment for all strains of influenza
5. New Website Created Just For Car Accident Victims… Reveals Chiropractic Treatment Is Extremely Effective For Whiplash, Neck and Back Pain
6. The Harley Medical group launches exclusive treatment for stretch marks and scars
7. Local Walgreen's Drug Stores Now Stock ZymaDerm™ The Painless Treatment for Molluscum Contagiosum
8. UT Southwestern investigators perform head-to-head comparison of incontinence treatments
9. New cancer guidelines: Exercise during and after treatment is now encouraged
10. Acne Treatment Reviewed by Leading Dermatologists in Honor of Acne Awareness Month
11. Hair Loss Research Study Reveals Important Breakthrough in the Treatment of Male Pattern Baldness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... July 19, 2017 , ... A July ... lead to, or worsen, varicose veins in some patients, according to medical experts. ... certain not-so-good practices, like excessive sitting or standing, or regularly nicking yourself while ...
(Date:7/18/2017)... ... July 18, 2017 , ... ClinicalTrials.gov and the New ... Need to Consider?, **An FDAnews Webinar**, Aug. 2, 2017 — 1:30 p.m. – ... Rule for Clinical Trials Registration and Results Information,” is a head-scratcher. After reading ...
(Date:7/18/2017)... , ... July 18, 2017 , ... Heritage Woods of ... 11 a.m. to 12:30 p.m. on Aug. 15. , The community, which is located ... those on Medicaid, who need some help to maintain their independence. , The lunch ...
(Date:7/17/2017)... ... July 17, 2017 , ... McGraw Family Pledges $3 Million for New ... Generation of Healthcare Clinicians , NORWALK, Connecticut – July 17, 2017 – The ... investing in community health by pledging up to $3 million in a challenge gift ...
(Date:7/17/2017)... Louis, MO (PRWEB) , ... July 17, 2017 ... ... and higher education recruitment firm, recently completed a nationwide executive search for Springfield ... aggressive timeline, Springfield Clinic named Ray Williams, a skilled healthcare executive with more ...
Breaking Medicine News(10 mins):
(Date:7/5/2017)... Wolfmet 3D  printed tungsten collimator manufactured by M&I Materials proves to ... progress molecular radiotherapy imaging. In molecular radiotherapy (MRT) ... quantify the radiation absorbed by those patients undergoing treatment. As ... radiotherapy treatment has been available — that is, until now. ... ...
(Date:7/5/2017)... of over 2,000 employees and a leader in environmental and life science testing, ... position as the top American owned and operated environmental testing firm in ... ... The ... , enhances Pace Analytical,s capability as an innovative full service provider in the ...
(Date:7/1/2017)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) ... will be broadcast live over the Internet on Thursday, July ... detailing the quarterly results will be made available at 7:30 ... The live audio webcast can be accessed via Zimmer ... be archived for replay following the conference call. ...
Breaking Medicine Technology: